Biomarkers in early diagnosis and screening of lung cancer
10.3760/cma.j.issn.1674-0815.2017.04.018
- VernacularTitle:生物标记物应用于肺癌早期诊断和筛查研究进展
- Author:
Shijia ZHANG
;
Jing ZHAO
;
Shengxiang REN
;
Caicun ZHOU
- Keywords:
Biological markers;
Early diagnosis;
Lung neoplasms;
Screening
- From:
Chinese Journal of Health Management
2017;11(4):383-387
- CountryChina
- Language:Chinese
-
Abstract:
Early diagnosis and screening are of great significance for improving the prognosis of patients with lung cancer. Low-dose helical computed tomography (LDCT) reduces lung cancer mortality by about 20％, making it the most effective screening tool. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of biomarkers such as noninvasive autoantibody and plasma/serum microRNA (miRNA) were shown in several studies, making them approved for early diagnosis in our country, Europe and the United States, and their role in screening is being explored in ongoing studies.
